BioSpace News Archive

ABVC BioPharma, Inc. today announced that the Vitrargus® Phase II study at the Sydney Eye Hospital in New South Wales, Australia received ethical approval from the St. Vincent’s Hospital Melbourne Human Research Ethics Committee (HREC) on May 15, 2023.

Coherus BioSciences, Inc. today announced that the single-dose (6mg/0.6mL), prefilled autoinjector presentation of UDENYCA® (pegfilgrastim-cbqv) is now available for commercial sale in the United States.

Microbot Medical Inc., the developer of the LIBERTY® Surgical Robotic System, the first single-use endovascular robotic system, announced a highly successful extended joint pre- clinical animal study held at a leading European-based research lab.

Clearmind Medicine Inc. today announced the selection of its first U.S. site for the company’s Phase I/IIa clinical trial of its proprietary MEAI-based CMND-100 compound for the treatment of alcohol use disorder (“AUD”).

Anixa Biosciences, Inc. today announced that, in conjunction with its partner Moffitt Cancer Center, it has commenced treatment of the second patient in the ongoing clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.

Creative Medical Technology Holdings, Inc. announced significant advances in the ongoing development of its ImmCelz® platform, the Company’s cell-free system which has previously been validated to supercharge a patient’s own cells to treat a number of immune disorders.

Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Vafseo ® (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.

GRI Bio, Inc. today provided a business outlook and highlighted upcoming milestones for its innovative pipeline of NKT cell modulators in development.

Royal Philips, a global leader in health technology, and Vanderbilt University Medical Center, home to the top-ranked adult and pediatric hospitals in the Southeastern U.S., announced a collaboration that aims to reduce the health system’s carbon footprint while determining a blueprint to guide industry efforts.

Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announced that the Company has been issued a patent by the Japan Patent Office protecting its PD1-41BB switch receptor.